Dysuria News and Research

RSS

Asahi Kasei acquires ZOLL

Asahi Kasei Corporation, Japan's leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors, announced today the successful completion of its acquisition of ZOLL Medical Corporation, a major US manufacturer of medical devices for critical care, on April 26, 2012, US Eastern time.

27 Apr 2012

Asahi Kasei announces commencement of tender offer for ZOLL

Asahi Kasei Corporation, Japan's leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors, announced today the commencement of a tender offer through its indirect wholly owned U.S. subsidiary Asclepius Subsidiary Corporation for all outstanding shares of common stock of ZOLL Medical Corporation for $93 per share, net to the seller in cash, without interest and less any required withholding taxes.

26 Mar 2012

Asahi Kasei to acquire ZOLL

Asahi Kasei Corporation, and ZOLL Medical Corporation today jointly announced that Asahi Kasei, Japan's leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors, has entered into a definitive merger agreement with ZOLL, a manufacturer of resuscitation and critical care devices and related software solutions, pursuant to which Asahi Kasei will acquire ZOLL for approximately $2.21 billion.

12 Mar 2012

Salix enters definitive agreement to acquire Oceana Therapeutics

Salix Pharmaceuticals, Ltd. and Oceana Therapeutics, LLC today announced that they have entered into a definitive agreement whereby Salix will acquire all of the outstanding stock of Oceana Therapeutics, Inc., a privately-held global provider of gastroenterology and urology therapeutics, for $300 million in cash.

8 Nov 2011

FDA approves Allergan's BOTOX to treat specific form of urinary incontinence

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved BOTOX for injection for the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition in adults who have an inadequate response to or are intolerant of an anticholinergic medication.

25 Aug 2011

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Onconova Therapeutics, Inc., and SymBio Pharmaceuticals Limited announced today that they will collaborate to develop and commercialize rigosertib in Japan and Korea. Onconova is conducting late-stage clinical trials with rigosertib (ON 01910.Na) in the U.S., Europe and India for the treatment of Myelodysplastic Syndromes (MDS) and solid tumors.

8 Jul 2011

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Onconova Therapeutics, Inc. announced two advances in the clinical development of ESTYBON (rigosertib, ON 01910.Na) in presentations at the annual meeting of the American Society of Clinical Oncology (ASCO), June 3-7, 2011, in Chicago, Illinois.

6 Jun 2011

Calypso System can precisely deliver radiation in post-prostatectomy patients

Calypso Medical Technologies, Inc., developer of GPS for the Body® technology used for the precise tracking of cancerous tumors during radiation therapy, is exhibiting at the American Urological Association Annual Meeting (booth 4337) and will discuss recent clinical findings suggesting that the Calypso® System can be used to more precisely deliver radiation in post-prostatectomy patients.

16 May 2011

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.

4 Jun 2010

Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that it has entered into an exclusive US $75 million license agreement with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of its PSA-activated pro-drug, PRX302, in Japan for BPH, prostate cancer and other diseases of the prostate. Protox retains exclusive rights to PRX302 in all other territories.

30 Apr 2010

Seminar highlights latest treatment options for common medical conditions that affect men

Dr. Y. Mark Hong, with Affiliated Urologists, a specialist in men's health issues, will be leading a free Men's Health Seminar on Thursday, January 21st. The program, to be held at 5:00 pm at the Moon Valley Country Club, will explain the latest treatment options for one of the most common conditions affecting men today: Benign Prostate Hyperplasia (also known as Enlarged Prostate). A question and answer period will follow the program.

8 Jan 2010

Long-term complications for children fed with melamine contaminated products

Children with a history of consuming melamine-contaminated milk powder are at an increased risk of developing kidney stones and other urological complications.

26 Apr 2009

Smoking causes bladder cancer

The Great American Smokeout is this Thursday, and the American Urological Association (AUA) gives smokers another good reason to quit: Smoking causes bladder cancer.

17 Nov 2008

Saw Palmetto for enlarged prostate

Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.

6 Nov 2008

Bladder conditions - raising awareness

November is Bladder Health Month, and there's no better time to raise awareness of the bladder conditions that affect millions of patients, who often suffer in silence with common, treatable symptoms.

4 Nov 2008

Alfuzosin may improve double-J stent related symptoms

The first indwelling endoluminal ureteral stent was described over 30 years ago and has since become a routine and indispensable urologic tool. However, the side effects and patient morbidity associated with ureteral stents are not insignificant.

9 Mar 2006